Stories tagged 'John Thompson'
7 skin cancer myths — debunked
Experts take on base tans and other ‘complete baloney’ standing in the way of skin health
Aug. 2, 2017 | By Susan Keown / Fred Hutch News Service
From indoor tanning to sunscreen use: Lower your risk of skin cancer by confronting these myths head on.
Good News at Fred Hutch
Celebrating faculty and staff achievements
Nov. 14, 2016
Good News: Drs. Harmit Malik, Jesse Bloom win ASM awards; Fred Hutch team launches personalized anticancer vaccine project
Tags: Bezos, Bezos Family Immunotherapy Clinic, cancer immunotherapy, cancer vaccine, evolutionary biologist, Harmit Malik, immunotherapy, Immunotherapy Integrated Research Center, Jesse Bloom, John Thompson, Martin McIntosh, McGarry Houghton, Molecular basis of cancer , Stanley R Riddell, Sylvia Lee, therapeutic vaccine, Transplant and Immunotherapy, Tumor specific translational research
Cancer Immunotherapy Trials Network selects member sites
Center-based initiative announces 27 institutional partners in national research effort to accelerate clinical trials of promising cancer immunotherapies
April 11, 2011
Research institutions at 27 sites across North America have been selected as part of the Cancer Immunotherapy Trials Network, based at the Fred Hutchinson Cancer Research Center. A new initiative in immunotherapy, CITN unites top academic immunologists to conduct multicenter research on therapies that boost patients’ own immune systems to fight cancer.
SCCA opens Northwest’s first academic phase 1 Clinical Trials Unit
Facility will increase earlier access to promising new drugs
June 14, 2010 | By Dean Forbes
A dedicated space for cancer patients volunteering to be part of first-phase clinical drug studies has opened at the Seattle Cancer Care Alliance. The phase 1 Clinical Trials Unit is the Pacific Northwest’s first such academic-based program and serves the Fred Hutchinson/University of Washington Cancer Consortium.
Encouraging results for renal-cell cancer trial
An international team of investigators report progression-free survival in patients treated with IL-21 combined with Nexavar after failure of prior therapy
June 1, 2009
Researchers at ZymoGenetics, Inc. announced positive final results from a phase 2 clinical trial in patients receiving second or third-line therapy for advanced renal cell carcinoma with the combination of recombinant Interleukin 21 (IL-21) and Nexavar® (sorafenib) tablets. The combination demonstrated considerable clinical benefit, with an overall response rate of 21 percent, a disease-control rate of 82 percent, and progression-free survival of 5.7 months in this heavily pretreated population.
John Thompson named director Consortium's phase I trials
Oct. 1, 2007Tags: Clinical Research, John Thompson, Melanoma
(RSS feeds are best viewed in browsers other than Chrome)
Editor's Picks
Acupuncture can curb treatment-related joint pain in breast cancer patients
GIVE NOW &
SAVE LIVES
Story Archive
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
2008
2007
2006
2005
2004
2003
2002
2001
2000
1999
1998
1997
Publications
Magazine Archive
Back issues of Hutch Magazine
Financial Reporting
Fiscal highlights & Annual Reports
Science Spotlight
Monthly review of Center-authored papers
Fred Hutch News
Get updates via email.
